SLDB Earnings — Solid Biosciences Inc. Common Stock Post-ER Performance | BigEarnings
SLDB — Solid Biosciences Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$7.34
Market Cap$722.6M
P/E—
52W Range$3.06 – $8.87
Next Earnings2026-08-11
About Solid Biosciences Inc. Common Stock
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
